# Study Assessing AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

> **NCT03739593** · PHASE2 · COMPLETED · sponsor: **Aerie Pharmaceuticals** · enrollment: 49 (actual)

## Conditions studied

- Macular Edema

## Interventions

- **DRUG:** AR-1105-CF1
- **DRUG:** AR-1105-CF2

## Key facts

- **NCT ID:** NCT03739593
- **Lead sponsor:** Aerie Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-13
- **Primary completion:** 2020-05-14
- **Final completion:** 2020-07-09
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2022-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03739593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03739593, "Study Assessing AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03739593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*